Trial Watch: Dendritic cell-based interventions for cancer therapy

OncoImmunology

Volumn 2, Issue 10, 2013, Pages

  Vacchelli, Erika ^a,b,c   Vitale, Ilio ^d,e   Eggermont, Alexander ^b   Fridman, Wolf Hervé ^f,g,h   Fučíková, Jitka ^f,g,h,i,j   Cremer, Isabelle ^g,h,k   Galon, Jérôme ^g,h,k,l   Tartour, Eric ^f,g,l   Zitvogel, Laurence ^b,m   Kroemer, Guido ^c,f,g,h,n   Galluzzi, Lorenzo ^a,f,h  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c Institut Gustave Roussy   (France)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^h CENTRE DE RECHERCHE DES CORDELIERS   (France)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j Sotio   (Czech Republic)

^k SORBONNE UNIVERSITÉ   (France)

^l INSER M U872   (France)

^m University Paris XI   (France)

ⁿ Metabolomics Platform   (France)

more..

Author keywords

Antigen presenting cells; Immunogenic cell death; Monoclonal antibodies; Plasmacytoid dendritic cells; Regulatory T cells; Toll like receptors

Indexed keywords

CYCLOPHOSPHAMIDE; DASATINIB; DENDRITIC CELL VACCINE; DNA VACCINE; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; INTERLEUKIN 2; IPILIMUMAB; LENALIDOMIDE; SIPULEUCEL T; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADAPTIVE IMMUNITY; ADVANCED CANCER; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN CANCER; BRAIN METASTASIS; BREAST CARCINOMA; CANCER IMMUNIZATION; CELL THERAPY; CELLULAR IMMUNITY; COLORECTAL CANCER; DENDRITIC CELL; DRUG APPROVAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; ELECTRON THERAPY; GLIOBLASTOMA; GLIOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INTERVENTION STUDY; INTRADUCTAL CARCINOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SOLID TUMOR; TARGET CELL;

EID: 84890254287     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25771     Document Type: Article

References (368)

1. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973; 137:1142-62; PMID:4573839; http:// dx.doi.org/10.1084/jem.137.5.1142
2. Lanzavecchia A, Sallusto F, Ralph M. Ralph M. Steinman 1943-2011. Cell 2011; 147:1216-7; PMID:22263224; http://dx.doi.org/10.1016/j. cell.2011.11.040
3. Nussenzweig MC, Mellman I. Ralph Steinman (1943-2011). Nature 2011; 478:460; PMID:22031432; http://dx.doi.org/10.1038/478460a
4. Mellman I, Nussenzweig M. Retrospective. Ralph M. Steinman (1943-2011). Science 2011; 334:466; PMID:22034425; http://dx.doi.org/10.1126/science. 1215136
5. Banchereau J, Paczesny S, Blanco P, Bennett L, Pascual V, Fay J, et al. Dendritic cells: controllers of the immune system and a new promise for immunotherapy. Ann N Y Acad Sci 2003; 987:180-7; PMID:12727638; http:// dx.doi.org/10.1111/j.1749-6632.2003.tb06047.x
6. Klechevsky E, Flamar AL, Cao Y, Blanck JP, Liu M, O'Bar A, et al. Cross-priming CD8+ T cells by targeting antigens to human dendritic cells through DCIR. Blood 2010; 116:1685-97; PMID:20530286; http:// dx.doi.org/10.1182/blood-2010-01-264960
7. Banchereau J, Schuler-Thurner B, Palucka AK, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106:271-4; PMID:11509176; http://dx.doi. org/10.1016/S0092-8674(01)00448-2
8. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 2003; 19:225-34; PMID:12932356; http://dx.doi.org/10.1016/S1074-7613(03)00208-5
9. Palucka AK, Ueno H, Fay JW, Banchereau J. Taming cancer by inducing immunity via dendritic cells. Immunol Rev 2007; 220:129-50; PMID:17979844; http://dx.doi.org/10.1111/j.1600-065X.2007.00575.x
10. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, et al. Dendritic cell subsets in health and disease. Immunol Rev 2007; 219:118-42; PMID:17850486; http://dx.doi.org/10.1111/j.1600-065X.2007.00551.x
11. Banchereau J, Pulendran B, Steinman R, Palucka K. Will the making of plasmacytoid dendritic cells in vitro help unravel their mysteries?. J Exp Med 2000; 192:F39-44; PMID:11120782; http://dx.doi. org/10.1084/jem.192.12.F39
12. Berard F, Blanco P, Davoust J, Neidhart-Berard EM, Nouri-Shirazi M, Taquet N, et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J Exp Med 2000; 192:1535-44; PMID:11104796; http://dx.doi.org/10.1084/jem.192.11.1535
13. Li D, Romain G, Flamar AL, Duluc D, Dullaers M, Li XH, et al. Targeting self-and foreign antigens to dendritic cells via DC-ASGPR generates IL-10-producing suppressive CD4+ T cells. J Exp Med 2012; 209:109-21; PMID:22213806; http://dx.doi.org/10.1084/ jem.20110399
14. Jotwani R, Palucka AK, Al-Quotub M, Nouri-Shirazi M, Kim J, Bell D, et al. Mature dendritic cells infiltrate the T cell-rich region of oral mucosa in chronic periodontitis: in situ, in vivo, and in vitro studies. J Immunol 2001; 167:4693-700; PMID:11591800
15. Matsui T, Connolly JE, Michnevitz M, Chaussabel D, Yu CI, Glaser C, et al. CD2 distinguishes two subsets of human plasmacytoid dendritic cells with distinct phenotype and functions. J Immunol 2009; 182:6815-23; PMID:19454677; http://dx.doi.org/10.4049/jimmunol. 0802008
16. Nouri-Shirazi M, Banchereau J, Bell D, Burkeholder S, Kraus ET, Davoust J, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol 2000; 165:3797-803; PMID:11034385
17. Rolland A, Guyon L, Gill M, Cai YH, Banchereau J, McClain K, et al. Increased blood myeloid dendritic cells and dendritic cell-poietins in Langerhans cell histiocytosis. J Immunol 2005; 174:3067-71; PMID:15728521
18. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol 2000; 1:510-4; PMID:11101873; http://dx.doi.org/10.1038/82763
19. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005; 5:296-306; PMID:15803149; http://dx.doi. org/10.1038/nri1592
20. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFNalpha in systemic lupus erythematosus. Science 2001; 294:1540-3; PMID:11711679; http://dx.doi. org/10.1126/science.1064890
21. Pulendran B, Palucka K, Banchereau J. Sensing pathogens and tuning immune responses. Science 2001; 293:253-6; PMID:11452116; http://dx.doi. org/10.1126/science.1062060
22. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52; PMID:9521319; http://dx.doi.org/10.1038/32588
23. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449:419-26; PMID:17898760; http://dx.doi.org/10.1038/nature06175
24. Merad M, Sathe P, Helft J, Miller J, Mortha A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev Immunol 2013; 31:563-604; PMID:23516985; http://dx.doi.org/10.1146/ annurev-immunol-020711-074950
25. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
26. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711; PMID:12615891; http://dx.doi. org/10.1146/annurev.immunol.21.120601.141040
27. Idoyaga J, Fiorese C, Zbytnuik L, Lubkin A, Miller J, Malissen B, et al. Specialized role of migratory dendritic cells in peripheral tolerance induction. J Clin Invest 2013; 123:844-54; PMID:23298832
28. Watkins SK, Hurwitz AA. FOXO3: A master switch for regulating tolerance and immunity in dendritic cells. Oncoimmunology 2012; 1:252-4; PMID:22720261; http://dx.doi.org/10.4161/onci.1.2.18241
29. Galluzzi L, Kepp O, Kroemer G. Mitochondria: master regulators of danger signalling. Nat Rev Mol Cell Biol 2012; 13:780-8; PMID:23175281; http://dx.doi. org/10.1038/nrm3479
30. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31:51-72; PMID:23157435; http://dx.doi.org/10.1146/annurev-immunol-032712-100008
31. Cirone M, Di Renzo L, Lotti LV, Conte V, Trivedi P, Santarelli R, et al. Activation of dendritic cells by tumor cell death. Oncoimmunology 2012; 1:1218-9; PMID:23170286; http://dx.doi.org/10.4161/ onci.20428
32. Galluzzi L, Senovilla L, Vacchelli E, Eggermont A, Fridman WH, Galon J, et al. Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012; 1:1111-34; PMID:23170259; http://dx.doi.org/10.4161/onci.21494
33. Jin P, Han TH, Ren J, Saunders S, Wang E, Marincola FM, et al. Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010; 8:4; PMID:20078880; http://dx.doi.org/10.1186/1479-5876-8-4
34. Quah BJ, O'Neill HC. Maturation of function in dendritic cells for tolerance and immunity. J Cell Mol Med 2005; 9:643-54; PMID:16202211; http://dx.doi. org/10.1111/j.1582-4934.2005.tb00494.x
35. Nakahara T, Moroi Y, Uchi H, Furue M. Differential role of MAPK signaling in human dendritic cell maturation and Th1/Th2 engagement. J Dermatol Sci 2006; 42:1-11; PMID:16352421; http://dx.doi. org/10.1016/j.jdermsci.2005.11.004
36. Hammer GE, Ma A. Molecular control of steadystate dendritic cell maturation and immune homeostasis. Annu Rev Immunol 2013; 31:743-91; PMID:23330953; http://dx.doi.org/10.1146/annurevimmunol-020711-074929
37. Reis e Sousa C. Dendritic cells in a mature age. Nat Rev Immunol 2006; 6:476-83; PMID:16691244; http:// dx.doi.org/10.1038/nri1845
38. Steinman RM. Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 2012; 30:1-22; PMID:22136168; http://dx.doi.org/10.1146/ annurev-immunol-100311-102839
39. Maldonado-López R, De Smedt T, Michel P, Godfroid J, Pajak B, Heirman C, et al. CD8alpha+ and CD8alpha-subclasses of dendritic cells direct the development of distinct T helper cells in vivo. J Exp Med 1999; 189:587-92; PMID:9927520; http:// dx.doi.org/10.1084/jem.189.3.587
40. Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999; 96:1036-41; PMID:9927689; http://dx.doi.org/10.1073/pnas.96.3.1036
41. Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007; 315:107-11; PMID:17204652; http:// dx.doi.org/10.1126/science.1136080
42. Ueno H, Palucka AK, Banchereau J. The expanding family of dendritic cell subsets. Nat Biotechnol 2010; 28:813-5; PMID:20697407; http://dx.doi. org/10.1038/nbt0810-813
43. Ueno H, Schmitt N, Klechevsky E, Pedroza-Gonzalez A, Matsui T, Zurawski G, et al. Harnessing human dendritic cell subsets for medicine. Immunol Rev 2010; 234:199-212; PMID:20193020; http://dx.doi. org/10.1111/j.0105-2896.2009.00884.x
44. Satpathy AT, Wu X, Albring JC, Murphy KM. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145-54; PMID:23160217; http://dx.doi. org/10.1038/ni.2467
45. Palucka K, Banchereau J. Human dendritic cell subsets in vaccination. Curr Opin Immunol 2013; 25:396-402; PMID:23725656; http://dx.doi.org/10.1016/j. coi.2013.05.001
46. Klechevsky E, Banchereau J. Human dendritic cells subsets as targets and vectors for therapy. Ann N Y Acad Sci 2013; 1284:24-30; PMID:23651190; http:// dx.doi.org/10.1111/nyas.12113
47. Klechevsky E, Morita R, Liu M, Cao Y, Coquery S, Thompson-Snipes L, et al. Functional specializations of human epidermal Langerhans cells and CD14+ dermal dendritic cells. Immunity 2008; 29:497-510; PMID:18789730; http://dx.doi.org/10.1016/j.immuni. 2008.07.013
48. Bachem A, Güttler S, Hartung E, Ebstein F, Schaefer M, Tannert A, et al. Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells. J Exp Med 2010; 207:1273-81; PMID:20479115; http://dx.doi.org/10.1084/jem.20100348
49. Crozat K, Guiton R, Contreras V, Feuillet V, Dutertre CA, Ventre E, et al. The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1283-92; PMID:20479118; http://dx.doi. org/10.1084/jem.20100223
50. Jongbloed SL, Kassianos AJ, McDonald KJ, Clark GJ, Ju X, Angel CE, et al. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med 2010; 207:1247-60; PMID:20479116; http:// dx.doi.org/10.1084/jem.20092140
51. Poulin LF, Salio M, Griessinger E, Anjos-Afonso F, Craciun L, Chen JL, et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med 2010; 207:1261-71; PMID:20479117; http://dx.doi. org/10.1084/jem.20092618
52. Joffre OP, Segura E, Savina A, Amigorena S. Crosspresentation by dendritic cells. Nat Rev Immunol 2012; 12:557-69; PMID:22790179; http://dx.doi. org/10.1038/nri3254
53. Shortman K, Heath WR. The CD8+ dendritic cell subset. Immunol Rev 2010; 234:18-31; PMID:20193009; http://dx.doi.org/10.1111/j.0105-2896.2009.00870.x
54. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999; 284:1835-7; PMID:10364556; http:// dx.doi.org/10.1126/science.284.5421.1835
55. Cella M, Facchetti F, Lanzavecchia A, Colonna M. Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization. Nat Immunol 2000; 1:305-10; PMID:11017101; http:// dx.doi.org/10.1038/79747
56. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, et al. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 2002; 195:953-8; PMID:11927638; http://dx.doi.org/10.1084/ jem.20020045
57. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194:863-9; PMID:11561001; http://dx.doi. org/10.1084/jem.194.6.863
58. Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218:74-86; PMID:12470615; http://dx.doi. org/10.1016/S0008-8749(02)00517-8
59. Kadowaki N, Liu YJ. Natural type I interferonproducing cells as a link between innate and adaptive immunity. Hum Immunol 2002; 63:1126-32; PMID:12480256; http://dx.doi.org/10.1016/S0198-8859(02)00751-6
60. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 2011; 365:127-38; PMID:21524210; http:// dx.doi.org/10.1056/NEJMoa1100066
61. Lambrecht BN, Hammad H. Taking our breath away: dendritic cells in the pathogenesis of asthma. Nat Rev Immunol 2003; 3:994-1003; PMID:14647481; http:// dx.doi.org/10.1038/nri1249
62. Miller E, Bhardwaj N. Dendritic cell dysregulation during HIV-1 infection. Immunol Rev 2013; 254:170-89; PMID:23772620; http://dx.doi.org/10.1111/ imr.12082
63. Zitvogel L, Tesniere A, Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006; 6:715-27; PMID:16977338; http://dx.doi.org/10.1038/nri1936
64. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi.org/10.1126/science. 1203486
65. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; PMID:22301798; http://dx.doi.org/10.1038/nrd3626
66. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of anticancer agents: Reinstating immunosurveillance. Immunity 2013; Forthcoming; http://dx.doi.org/10.1016/j.immuni.2013.06.014.
67. Scarlett UK, Rutkowski MR, Rauwerdink AM, Fields J, Escovar-Fadul X, Baird J, et al. Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. J Exp Med 2012; 209:495-506; PMID:22351930; http://dx.doi.org/10.1084/ jem.20111413
68. Tomihara K, Guo M, Shin T, Sun X, Ludwig SM, Brumlik MJ, et al. Antigen-specific immunity and cross-priming by epithelial ovarian carcinoma-induced CD11b(+)Gr-1(+) cells. J Immunol 2010; 184:6151-60; PMID:20427766; http://dx.doi.org/10.4049/jimmunol. 0903519
69. Chaput N, Conforti R, Viaud S, Spatz A, Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008; 27:5920-31; PMID:18836473; http://dx.doi. org/10.1038/onc.2008.270
70. Taieb J, Chaput N, Ménard C, Apetoh L, Ullrich E, Bonmort M, et al. A novel dendritic cell subset involved in tumor immunosurveillance. Nat Med 2006; 12:214-9; PMID:16444265; http://dx.doi. org/10.1038/nm1356
71. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H, et al. Anticancer chemotherapyinduced intratumoral recruitment and differentiation of antigen-presenting cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j. immuni.2013.03.003
72. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science 2012; 337:1678-84; PMID:23019653; http://dx.doi.org/10.1126/science. 1224922
73. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334:1573-7; PMID:22174255; http://dx.doi.org/10.1126/science. 1208347
74. Noessner E, Brech D, Mendler AN, Masouris I, Schlenker R, Prinz PU. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1:1451-3; PMID:23243626; http://dx.doi.org/10.4161/ onci.21356
75. Sisirak V, Faget J, Vey N, Blay JY, Ménétrier-Caux C, Caux C, et al. Plasmacytoid dendritic cells deficient in IFNa production promote the amplification of FOXP3(+) regulatory T cells and are associated with poor prognosis in breast cancer patients. Oncoimmunology 2013; 2:e22338; PMID:23482834; http://dx.doi.org/10.4161/onci.22338
76. Reichert TE, Scheuer C, Day R, Wagner W, Whiteside TL. The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer 2001; 91:2136-47; PMID:11391595; http://dx.doi.org/10.1002/1097-0 1 4 2 ( 2 0 0 1 0 6 0 1 ) 9 1 : 1 1 2 1 3 6 : : A I D -CNCR12423.0.CO;2-Q
77. Ikeguchi M, Ikeda M, Tatebe S, Maeta M, Kaibara N. Clinical significance of dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 1998; 5:1185-9; PMID:9683832
78. Ishigami S, Natsugoe S, Matsumoto M, Okumura H, Sakita H, Nakashima S, et al. Clinical implications of intratumoral dendritic cell infiltration in esophageal squamous cell carcinoma. Oncol Rep 2003; 10:1237-40; PMID:12883687
79. Kakeji Y, Maehara Y, Korenaga D, Tsujitani S, Haraguchi M, Watanabe A, et al. Prognostic significance of tumor-host interaction in clinical gastric cancer: relationship between DNA ploidy and dendritic cell infiltration. J Surg Oncol 1993; 52:207-12; PMID:8468980; http://dx.doi.org/10.1002/ jso.2930520402
80. Ishigami S, Aikou T, Natsugoe S, Hokita S, Iwashige H, Tokushige M, et al. Prognostic value of HLA-DR expression and dendritic cell infiltration in gastric cancer. Oncology 1998; 55:65-9; PMID:9428378; http:// dx.doi.org/10.1159/000011837
81. Okuyama T, Maehara Y, Kakeji Y, Tsuijitani S, Korenaga D, Sugimachi K. Interrelation between tumor-associated cell surface glycoprotein and host immune response in gastric carcinoma patients. Cancer 1998; 82:1468-75; PMID:9554522; http://dx.doi.org/10.1002/ (SICI)1097-0142(19980415)82:81468::AIDCNCR6 3.0.CO;2-5
82. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Xiangming C, Iwashige H, et al. Clinical impact of intratumoral natural killer cell and dendritic cell infiltration in gastric cancer. Cancer Lett 2000; 159:103-8; PMID:10974412; http://dx.doi.org/10.1016/S0304-3835(00)00542-5
83. Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Ohro S, et al. Prediction of sites of recurrence in gastric carcinoma using immunohistochemical parameters. J Surg Oncol 2007; 95:123-8; PMID:17262742; http:// dx.doi.org/10.1002/jso.20612
84. Daud AI, Mirza N, Lenox B, Andrews S, Urbas P, Gao GX, et al. Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor. J Clin Oncol 2008; 26:3235-41; PMID:18591558; http://dx.doi. org/10.1200/JCO.2007.13.9048
85. Cai XY, Gao Q, Qiu SJ, Ye SL, Wu ZQ, Fan J, et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006; 132:293-301; PMID:16421755; http://dx.doi. org/10.1007/s00432-006-0075-y
86. Yin XY, Lu MD, Lai YR, Liang LJ, Huang JF. Prognostic significances of tumor-infiltrating S-100 positive dendritic cells and lymphocytes in patients with hepatocellular carcinoma. Hepatogastroenterology 2003; 50:1281-4; PMID:14571719
87. Nakakubo Y, Miyamoto M, Cho Y, Hida Y, Oshikiri T, Suzuoki M, et al. Clinical significance of immune cell infiltration within gallbladder cancer. Br J Cancer 2003; 89:1736-42; PMID:14583778; http://dx.doi. org/10.1038/sj.bjc.6601331
88. Honig A, Schaller N, Dietl J, Backe J, Kammerer U. S100 as an immunohistochemically-detected marker with prognostic significance in endometrial carcinoma. Anticancer Res 2005; 25(3A):1747-53; PMID:16033094
89. Chang KC, Huang GC, Jones D, Lin YH. Distribution patterns of dendritic cells and T cells in diffuse large B-cell lymphomas correlate with prognoses. Clin Cancer Res 2007; 13:6666-72; PMID:18006767; http://dx.doi.org/10.1158/1078-0432.CCR-07-0504
90. Furihata M, Ohtsuki Y, Sonobe H, Araki K, Ogata T, Toki T, et al. Prognostic significance of simultaneous infiltration of HLA-DR-positive dendritic cells and tumor infiltrating lymphocytes into human esophageal carcinoma. Tohoku J Exp Med 1993; 169:187-95; PMID:8248911; http://dx.doi.org/10.1620/ tjem.169.187
91. Iwamoto M, Shinohara H, Miyamoto A, Okuzawa M, Mabuchi H, Nohara T, et al. Prognostic value of tumor-infiltrating dendritic cells expressing CD83 in human breast carcinomas. Int J Cancer 2003; 104:92-7; PMID:12532424; http://dx.doi.org/10.1002/ ijc.10915
92. Dieu-Nosjean MC, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-7; PMID:18802153; http://dx.doi. org/10.1200/JCO.2007.15.0284
93. Sautès-Fridman C, Cherfils-Vicini J, Damotte D, Fisson S, Fridman WH, Cremer I, et al. Tumor microenvironment is multifaceted. Cancer Metastasis Rev 2011; 30:13-25; PMID:21271351; http://dx.doi. org/10.1007/s10555-011-9279-y
94. Ladányi A, Kiss J, Somlai B, Gilde K, Fejos Z, Mohos A, et al. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother 2007; 56:1459-69; PMID:17279413; http://dx.doi.org/10.1007/s00262-007-0286-3
95. Kobayashi M, Suzuki K, Yashi M, Yuzawa M, Takayashiki N, Morita T. Tumor infiltrating dendritic cells predict treatment response to immmunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007; 27:1137-41; PMID:17465253
96. Conrad C, Gilliet M. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison. Oncoimmunology 2013; 2:e23887; PMID:23762788; http://dx.doi.org/10.4161/ onci.23887
97. Ishigami S, Ueno S, Matsumoto M, Okumura H, Arigami T, Uchikado Y, et al. Prognostic value of CD208-positive cell infiltration in gastric cancer. Cancer Immunol Immunother 2010; 59:389-95; PMID:19760221; http://dx.doi.org/10.1007/s00262-009-0758-8
98. Sandel MH, Dadabayev AR, Menon AG, Morreau H, Melief CJ, Offringa R, et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res 2005; 11:2576-82; PMID:15814636; http://dx.doi.org/10.1158/1078-0432.CCR-04-1448
99. Treilleux I, Blay JY, Bendriss-Vermare N, Ray-Coquard I, Bachelot T, Guastalla JP, et al. Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res 2004; 10:7466-74; PMID:15569976; http://dx.doi.org/10.1158/1078-0432.CCR-04-0684
100. Jensen TO, Schmidt H, Møller HJ, Donskov F, Høyer M, Sjoegren P, et al. Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer 2012; 118:2476-85; PMID:21953023; http://dx.doi.org/10.1002/ cncr.26511
101. Labidi-Galy SI, Treilleux I, Goddard-Leon S, Combes JD, Blay JY, Ray-Coquard I, et al. Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology 2012; 1:380-2; PMID:22737622; http://dx.doi.org/10.4161/ onci.18801
102. Zitvogel L, Kroemer G. Targeting dendritic cell metabolism in cancer. Nat Med 2010; 16:858-9; PMID:20689548; http://dx.doi.org/10.1038/ nm0810-858
103. Kreutz M, Tacken PJ, Figdor CG. Targeting dendritic cells--why bother?. Blood 2013; 121:2836-44; PMID:23390195; http://dx.doi.org/10.1182/blood-2012-09-452078
104. Garcia F, Climent N, Guardo AC, Gil C, Leon A, Autran B, et al. A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med 2013; 5:166ra2.
105. Lombardi V, Akbari O. Dendritic cell modulation as a new interventional approach for the treatment of asthma. Drug News Perspect 2009; 22:445-51; PMID:20016853
106. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004; 305:200-5; PMID:15247469; http://dx.doi.org/10.1126/science. 1100369
107. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med 2004; 10:475-80; PMID:15122249; http:// dx.doi.org/10.1038/nm1039
108. Nabel GJ. Designing tomorrow's vaccines. N Engl J Med 2013; 368:551-60; PMID:23388006; http:// dx.doi.org/10.1056/NEJMra1204186
109. Gross CC, Wiendl H. Dendritic cell vaccination in autoimmune disease. Curr Opin Rheumatol 2013; 25:268-74; PMID:23370378; http://dx.doi. org/10.1097/BOR.0b013e32835cb9f2
110. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al.; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/ NEJMoa1001294
111. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, et al. Sipuleucel-T. Nat Rev Drug Discov 2010; 9:513-4; PMID:20592741; http:// dx.doi.org/10.1038/nrd3220
112. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011; 17:3520-6; PMID:21471425; http://dx.doi.org/10.1158/1078-0432.CCR-10-3126
113. Satoh Y, Esche C, Gambotto A, Shurin GV, Yurkovetsky ZR, Robbins PD, et al. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol 2002; 2:337-49; PMID:12440225; http://dx.doi.org/10.1046/j.1359-4117.2002.01050.x
114. Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res 1999; 59:4035-41; PMID:10463604
115. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Clin Cancer Res 2004; 10:2891-901; PMID:15102698; http:// dx.doi.org/10.1158/1078-0432.CCR-03-0380
116. Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, et al. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res 2006; 66:8887-96; PMID:16951206; http://dx.doi. org/10.1158/0008-5472.CAN-05-3448
117. Endo H, Saito T, Kenjo A, Hoshino M, Terashima M, Sato T, et al. Phase I trial of preoperative intratumoral injection of immature dendritic cells and OK-432 for resectable pancreatic cancer patients. J Hepatobiliary Pancreat Sci 2012; 19:465-75; PMID:21983893; http://dx.doi.org/10.1007/s00534-011-0457-7
118. You CX, Shi M, Liu Y, Cao M, Luo R, Hermonat PL. AAV2/IL-12 gene delivery into dendritic cells (DC) enhances CTL stimulation above other IL-12 applications: Evidence for IL-12 intracrine activity in DC. Oncoimmunology 2012; 1:847-55; PMID:23162752; http://dx.doi.org/10.4161/onci.20504
119. Bol KF, Tel J, de Vries IJ, Figdor CG. Naturally circulating dendritic cells to vaccinate cancer patients. Oncoimmunology 2013; 2:e23431; PMID:23802086; http://dx.doi.org/10.4161/onci.23431
120. Nair SK, Snyder D, Rouse BT, Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 1997; 70:706-15; PMID:9096653; h t t p : / / d x . d o i . o r g / 1 0 . 1 0 0 2 / ( S I C I ) 1 0 9 7 -0215(19970317)70:6706::AID-IJC133.0.CO;2-7
121. DeMatos P, Abdel-Wahab Z, Vervaert C, Hester D, Seigler H. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. J Surg Oncol 1998; 68:79-91; PMID:9624036; h t t p : / / d x . d o i . o r g / 1 0 . 1 0 0 2 / ( S I C I ) 1 0 9 6 -9098(199806)68:279::AID-JSO33.0.CO;2-H
122. DeMatos P, Abdel-Wahab Z, Vervaert C, Seigler HF. Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. Cell Immunol 1998; 185:65-74; PMID:9636684; http://dx.doi. org/10.1006/cimm.1998.1277
123. Fields RC, Shimizu K, Mulé JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998; 95:9482-7; PMID:9689106; http://dx.doi.org/10.1073/pnas.95.16.9482
124. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 2001; 93:539-48; PMID:11477558; http://dx.doi. org/10.1002/ijc.1365
125. Paczesny S, Beranger S, Salzmann JL, Klatzmann D, Colombo BM. Protection of mice against leukemia after vaccination with bone marrow-derived dendritic cells loaded with apoptotic leukemia cells. Cancer Res 2001; 61:2386-9; PMID:11289101
126. Kokhaei P, Choudhury A, Mahdian R, Lundin J, Moshfegh A, Osterborg A, et al. Apoptotic tumor cells are superior to tumor cell lysate, and tumor cell RNA in induction of autologous T cell response in B-CLL. Leukemia 2004; 18:1810-5; PMID:15385926; http:// dx.doi.org/10.1038/sj.leu.2403517
127. Kokhaei P, Rezvany MR, Virving L, Choudhury A, Rabbani H, Osterborg A, et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 2003; 17:894-9; PMID:12750703; http:// dx.doi.org/10.1038/sj.leu.2402913
128. Albert ML, Sauter B, Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392:86-9; PMID:9510252; http://dx.doi.org/10.1038/32183
129. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998; 188:1359-68; PMID:9763615; http:// dx.doi.org/10.1084/jem.188.7.1359
130. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1:1297-302; PMID:7489412; http:// dx.doi.org/10.1038/nm1295-1297
131. Ossevoort MA, Feltkamp MC, van Veen KJ, Melief CJ, Kast WM. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J Immunother Emphasis Tumor Immunol 1995; 18:86-94; PMID:8574470; http:// dx.doi.org/10.1097/00002371-199508000-00002
132. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, et al. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 1996; 183:1357-65; PMID:8666894; http://dx.doi. org/10.1084/jem.183.4.1357
133. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-22; PMID:8551239; http://dx.doi.org/10.1084/ jem.183.1.317
134. Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998; 161:2094-8; PMID:9725199
135. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183:87-97; PMID:8551248; http://dx.doi.org/10.1084/ jem.183.1.87
136. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Garcia-Prats MD, DeLeo AB, et al. Bone marrowderived dendritic cells serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells 1997; 15:94-103; PMID:9090785; http://dx.doi.org/10.1002/ stem.150094
137. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999; 5:405-11; PMID:10202929; http://dx.doi. org/10.1038/7403
138. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184:465-72; PMID:8760800; http://dx.doi.org/10.1084/ jem.184.2.465
139. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997; 186:1177-82; PMID:9314567; http:// dx.doi.org/10.1084/jem.186.7.1177
140. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E. Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60:1028-34; PMID:10706120
141. Irvine AS, Trinder PK, Laughton DL, Ketteringham H, McDermott RH, Reid SC, et al. Efficient nonviral transfection of dendritic cells and their use for in vivo immunization. Nat Biotechnol 2000; 18:1273-8; PMID:11101806; http://dx.doi.org/10.1038/82383
142. Manickan E, Kanangat S, Rouse RJ, Yu Z, Rouse BT. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells. J Leukoc Biol 1997; 61:125-32; PMID:9021916
143. Song W, Kong HL, Carpenter H, Torii H, Granstein R, Rafii S, et al. Dendritic cells genetically modified with an adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med 1997; 186:1247-56; PMID:9334364; http://dx.doi.org/10.1084/ jem.186.8.1247
144. Tüting T, DeLeo AB, Lotze MT, Storkus WJ. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self " antigens induce antitumor immunity in vivo. Eur J Immunol 1997; 27:2702-7; PMID:9368629; http://dx.doi. org/10.1002/eji.1830271033
145. Wan Y, Bramson J, Carter R, Graham F, Gauldie J. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum Gene Ther 1997; 8:1355-63; PMID:9295130; http://dx.doi.org/10.1089/ hum.1997.8.11-1355
146. McArthur JG, Mulligan RC. Induction of protective anti-tumor immunity by gene-modified dendritic cells. J Immunother 1998; 21:41-7; PMID:9456435; http:// dx.doi.org/10.1097/00002371-199801000-00005
147. Ishida T, Chada S, Stipanov M, Nadaf S, Ciernik FI, Gabrilovich DI, et al. Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999; 117:244-51; PMID:10444254; http://dx.doi.org/10.1046/j.1365-2249.1999.00913.x
148. Tüting T, Steitz J, Brück J, Gambotto A, Steinbrink K, DeLeo AB, et al. Dendritic cell-based genetic immunization in mice with a recombinant adenovirus encoding murine TRP2 induces effective antimelanoma immunity. J Gene Med 1999; 1:400-6; PMID:10753065; http://dx.doi.org/10.1002/ (SICI)1521-2254(199911/12)1:6400::AIDJGM68 3.0.CO;2-D
149. Wan Y, Emtage P, Zhu Q, Foley R, Pilon A, Roberts B, et al. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Cell Immunol 1999; 198:131-8; PMID:10648127; http://dx.doi.org/10.1006/ cimm.1999.1585
150. Klein C, Bueler H, Mulligan RC. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J Exp Med 2000; 191:1699-708; PMID:10811863; http://dx.doi. org/10.1084/jem.191.10.1699
151. Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, et al. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother 2000; 23:59-66; PMID:10687138; http://dx.doi.org/10.1097/00002371-200001000-00008
152. Okada N, Saito T, Masunaga Y, Tsukada Y, Nakagawa S, Mizuguchi H, et al. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res 2001; 61:7913-9; PMID:11691812
153. Koido S, Kashiwaba M, Chen D, Gendler S, Kufe D, Gong J. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol 2000; 165:5713-9; PMID:11067929
154. Nair SK, Heiser A, Boczkowski D, Majumdar A, Naoe M, Lebkowski JS, et al. Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat Med 2000; 6:1011-7; PMID:10973321; http://dx.doi.org/10.1038/79519
155. Yamanaka R, Zullo SA, Tanaka R, Blaese M, Xanthopoulos KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001; 94:474-81; PMID:11235953; http://dx.doi. org/10.3171/jns.2001.94.3.0474
156. Insug O, Ku G, Ertl HC, Blaszczyk-Thurin M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002; 22(2A):613-21; PMID:12014629
157. Van Meirvenne S, Straetman L, Heirman C, Dullaers M, De Greef C, Van Tendeloo V, et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9:787-97; PMID:12189529; http://dx.doi.org/10.1038/ sj.cgt.7700499
158. Li M, You S, Ge W, Ma S, Ma N, Zhao C. Induction of T-cell immunity against leukemia by dendritic cells pulsed with total RNA isolated from leukemia cells. Chin Med J (Engl) 2003; 116:1655-61; PMID:14642130
159. Minami T, Nakanishi Y, Izumi M, Harada T, Hara N. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 2003; 26:420-31; PMID:12973031; http://dx.doi. org/10.1097/00002371-200309000-00005
160. Schmidt T, Ziske C, Märten A, Endres S, Tiemann K, Schmitz V, et al. Intratumoral immunization with tumor RNA-pulsed dendritic cells confers antitumor immunity in a C57BL/6 pancreatic murine tumor model. Cancer Res 2003; 63:8962-7; PMID:14695214
161. Jung CW, Kwon JH, Seol JG, Park WH, Hyun JM, Kim ES, et al. Induction of cytotoxic T lymphocytes by dendritic cells pulsed with murine leukemic cell RNA. Am J Hematol 2004; 75:121-7; PMID:14978690; http://dx.doi.org/10.1002/ajh.10471
162. Liu BY, Chen XH, Gu QL, Li JF, Yin HR, Zhu ZG, et al. Antitumor effects of vaccine consisting of dendritic cells pulsed with tumor RNA from gastric cancer. World J Gastroenterol 2004; 10:630-3; PMID:14991927
163. Zeis M, Siegel S, Wagner A, Schmitz M, Marget M, Kühl-Burmeister R, et al. Generation of cytotoxic responses in mice and human individuals against hematological malignancies using survivin-RNA-transfected dendritic cells. J Immunol 2003; 170:5391-7; PMID:12759413
164. Celluzzi CM, Falo LD Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J Immunol 1998; 160:3081-5; PMID:9531260
165. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J Immunol 1998; 161:5516-24; PMID:9820528
166. Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell Immunol 2002; 220:1-12; PMID:12718934; http://dx.doi.org/10.1016/S0008-8749(03)00009-1
167. Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell Immunol 2001; 213:4-13; PMID:11747351; http:// dx.doi.org/10.1006/cimm.2001.1864
168. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell Immunol 2003; 225:65-74; PMID:14698141; http://dx.doi.org/10.1016/j.cellimm. 2003.09.005
169. Sukhorukov VL, Reuss R, Endter JM, Fehrmann S, Katsen-Globa A, Gessner P, et al. A biophysical approach to the optimisation of dendritic-tumour cell electrofusion. Biochem Biophys Res Commun 2006; 346:829-39; PMID:16780801; http://dx.doi. org/10.1016/j.bbrc.2006.05.193
170. Cathelin D, Nicolas A, Bouchot A, Fraszczak J, Labbé J, Bonnotte B. Dendritic cell-tumor cell hybrids and immunotherapy: what's next?. Cytotherapy 2011; 13:774-85; PMID:21299362; http://dx.doi.org/10.31 09/14653249.2011.553593
171. Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, et al. Fusogenic membrane glycoproteinmediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 2006; 13:138-49; PMID:16136162; http://dx.doi.org/10.1038/sj.gt.3302609
172. Bonifaz LC, Bonnyay DP, Charalambous A, Darguste DI, Fujii S, Soares H, et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004; 199:815-24; PMID:15024047; http://dx.doi. org/10.1084/jem.20032220
173. Bonifaz L, Bonnyay D, Mahnke K, Rivera M, Nussenzweig MC, Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196:1627-38; PMID:12486105; http://dx.doi. org/10.1084/jem.20021598
174. Hawiger D, Inaba K, Dorsett Y, Guo M, Mahnke K, Rivera M, et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-79; PMID:11560993; http://dx.doi.org/10.1084/jem.194.6.769
175. Adotevi O, Vingert B, Freyburger L, Shrikant P, Lone YC, Quintin-Colonna F, et al. B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity. J Immunol 2007; 179:3371-9; PMID:17709554
176. Berraondo P, Nouzé C, Préville X, Ladant D, Leclerc C. Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive, and regulatory components of the immune system. Cancer Res 2007; 67:8847-55; PMID:17875726; http://dx.doi.org/10.1158/0008-5472.CAN-07-0321
177. Tacken PJ, de Vries IJ, Gijzen K, Joosten B, Wu D, Rother RP, et al. Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood 2005; 106:1278-85; PMID:15878980; http:// dx.doi.org/10.1182/blood-2005-01-0318
178. Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33:4229-39; PMID:22410170; http://dx.doi.org/10.1016/j.biomaterials. 2012.02.036
179. Schreibelt G, Klinkenberg LJ, Cruz LJ, Tacken PJ, Tel J, Kreutz M, et al. The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells. Blood 2012; 119:2284-92; PMID:22234694; http://dx.doi. org/10.1182/blood-2011-08-373944
180. Tacken PJ, Ginter W, Berod L, Cruz LJ, Joosten B, Sparwasser T, et al. Targeting DC-SIGN via its neck region leads to prolonged antigen residence in early endosomes, delayed lysosomal degradation, and cross-presentation. Blood 2011; 118:4111-9; PMID:21860028; http://dx.doi.org/10.1182/blood-2011-04-346957
181. Tacken PJ, Ter Huurne M, Torensma R, Figdor CG. Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking. Eur J Immunol 2012; 42:1989-98; PMID:22653683; http://dx.doi.org/10.1002/eji.201142258
182. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, Fokkink RG, et al. Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 2011; 118:6836-44; PMID:21967977; http://dx.doi. org/10.1182/blood-2011-07-367615
183. Wang B. Targeting dendritic cells in situ for breast cancer immunotherapy. Oncoimmunology 2012; 1:1398-400; PMID:23243606; http://dx.doi.org/10.4161/ onci.20982
184. García-Vallejo JJ, Unger WW, Kalay H, van Kooyk Y. Glycan-based DC-SIGN targeting to enhance antigen cross-presentation in anticancer vaccines. Oncoimmunology 2013; 2:e23040; PMID:23525136; http://dx.doi.org/10.4161/onci.23040
185. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998; 4:594-600; PMID:9585234; http://dx.doi.org/10.1038/nm0598-594
186. Théry C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999; 147:599-610; PMID:10545503; http://dx.doi. org/10.1083/jcb.147.3.599
187. Viaud S, Théry C, Ploix S, Tursz T, Lapierre V, Lantz O, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next?. Cancer Res 2010; 70:1281-5; PMID:20145139; http://dx.doi.org/10.1158/0008-5472.CAN-09-3276
188. Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL. Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands. Oncoimmunology 2012; 1:1074-83; PMID:23170255; http://dx.doi.org/10.4161/ onci.20897
189. Kandalaft LE, Powell DJ Jr., Chiang CL, Tanyi J, Kim S, Bosch M, et al. Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013; 2:e22664; PMID:23482679; http://dx.doi.org/10.4161/ onci.22664
190. Fucíková J, Rožková D, Ulcová H, Budinský V, Sochorová K, Pokorná K, et al. Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. J Transl Med 2011; 9:223; PMID:22208910; http://dx.doi. org/10.1186/1479-5876-9-223
191. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J, et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950
192. Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, et al. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients. J Immunother 2008; 31:101-12; PMID:18157017; http://dx.doi. org/10.1097/CJI.0b013e318159f5ba
193. Lee J, Boczkowski D, Nair S. Programming human dendritic cells with mRNA. Methods Mol Biol 2013; 969:111-25; PMID:23296931; http://dx.doi. org/10.1007/978-1-62703-260-5_8
194. Blalock LT, Landsberg J, Messmer M, Shi J, Pardee AD, Haskell R, et al. Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology 2012; 1:287-357; PMID:22737604; http://dx.doi.org/10.4161/onci.18628
195. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, et al. Fusions between dendritic cells and whole tumor cells as anticancer vaccines. Oncoimmunology 2013; 2:e24437; PMID:23762810; http://dx.doi.org/10.4161/onci.24437
196. Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, et al. Liposomal delivery of antigen to human dendritic cells. Vaccine 2003; 21:883-90; PMID:12547598; http://dx.doi.org/10.1016/S0264-410X(02)00536-4
197. van Broekhoven CL, Parish CR, Demangel C, Britton WJ, Altin JG. Targeting dendritic cells with antigencontaining liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy. Cancer Res 2004; 64:4357-65; PMID:15205352; http://dx.doi.org/10.1158/0008-5472.CAN-04-0138
198. Badiee A, Davies N, McDonald K, Radford K, Michiue H, Hart D, et al. Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205. Vaccine 2007; 25:4757-66; PMID:17512099; http://dx.doi.org/10.1016/j.vaccine. 2007.04.029
199. Gilboa E. DC-based cancer vaccines. J Clin Invest 2007; 117:1195-203; PMID:17476349; http://dx.doi. org/10.1172/JCI31205
200. Tacken PJ, de Vries IJ, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007; 7:790-802; PMID:17853902; http://dx.doi.org/10.1038/nri2173
201. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev Immunol 2003; 3:630-41; PMID:12974478; http://dx.doi.org/10.1038/nri1150
202. Finn OJ. Cancer immunology. N Engl J Med 2008; 358:2704-15; PMID:18565863; http://dx.doi. org/10.1056/NEJMra072739
203. Scanlon CS, D'Silva NJ. Personalized medicine for cancer therapy: Lessons learned from tumor-associated antigens. Oncoimmunology 2013; 2:e23433; PMID:23734304; http://dx.doi.org/10.4161/ onci.23433
204. Li Y, Cozzi PJ, Russell PJ. Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 2010; 30:67-101; PMID:19536865
205. Buonaguro L, Petrizzo A, Tornesello ML, Buonaguro FM. Translating tumor antigens into cancer vaccines. Clin Vaccine Immunol 2011; 18:23-34; PMID:21048000; http://dx.doi.org/10.1128/ CVI.00286-10
206. Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. Semin Immunol 2010; 22:125-31; PMID:20403708; http://dx.doi.org/10.1016/j. smim.2010.03.003
207. Mocellin S, Pilati P, Nitti D. Peptide-based anticancer vaccines: recent advances and future perspectives. Curr Med Chem 2009; 16:4779-96; PMID:19929787; http://dx.doi.org/10.2174/092986709789909648
208. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi. org/10.1158/1078-0432.CCR-09-0737
209. Cavallo F, Calogero RA, Forni G. Are oncoantigens suitable targets for anti-tumour therapy?. Nat Rev Cancer 2007; 7:707-13; PMID:17700704; http:// dx.doi.org/10.1038/nrc2208
210. Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, et al. Autoimmunity associated with immunotherapy of cancer. Blood 2011; 118:499-509; PMID:21531979; http://dx.doi. org/10.1182/blood-2011-01-325266
211. Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol 2008; 8:970-6; PMID:19008897; http://dx.doi.org/10.1038/ nri2438
212. Kaufman HL, Wolchok JD. Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy. J Clin Oncol 2006; 24:2230-2; PMID:16710020; http://dx.doi.org/10.1200/ JCO.2006.05.6952
213. Koon H, Atkins M. Autoimmunity and immunotherapy for cancer. N Engl J Med 2006; 354:758-60; PMID:16481646; http://dx.doi.org/10.1056/ NEJMe058307
214. Overwijk WW, Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol 2000; 20:433-50; PMID:11396680; http://dx.doi.org/10.1615/ CritRevImmunol.v20.i6.10
215. Kroemer G, Zitvogel L. Can the exome and the immunome converge on the design of efficient cancer vaccines?. Oncoimmunology 2012; 1:579-80; PMID:22934249; http://dx.doi.org/10.4161/ onci.20730
216. Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Toll-like receptor agonists for cancer therapy. OncoImmunology 2013; 2: Forthcoming; PMID:23162757.
217. Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology 2012; 1:1557-76; PMID:23264902; http://dx.doi. org/10.4161/onci.22428
218. Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial watch: FDAapproved Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:894-907; PMID:23162757; http://dx.doi.org/10.4161/onci.20931
219. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology 2012; 1:699-716; PMID:22934262; http://dx.doi.org/10.4161/ onci.20696
220. Wathelet N, Moser M. Role of dendritic cells in the regulation of antitumor immunity. Oncoimmunology 2013; 2:e23973; PMID:23734333; http://dx.doi. org/10.4161/onci.23973
221. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, et al. Trial Watch: Adoptive cell transfer immunotherapy. Oncoimmunology 2012; 1:306-15; PMID:22737606; http://dx.doi. org/10.4161/onci.19549
222. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; PMID:22720209; http://dx.doi.org/10.4161/ onci.1.1.17938
223. Menger L, Vacchelli E, Kepp O, Eggermont A, Tartour E, Zitvogel L, et al. Trial watch: Cardiac glycosides and cancer therapy. Oncoimmunology 2013; 2:e23082; PMID:23525565; http://dx.doi.org/10.4161/ onci.23082
224. Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596; http://dx.doi.org/10.4161/ onci.22009
225. Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, et al. Trial watch: DNA vaccines for cancer therapy. Oncoimmunology 2013; 2:e23803; PMID:23734328; http://dx.doi. org/10.4161/onci.23803
226. Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology 2013; 2:e24238; PMID:23762803; http://dx.doi.org/10.4161/onci.24238
227. Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Immunostimulatory cytokines. OncoImmunology 2013; 2:e24850; PMID:22754768
228. Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, et al. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; PMID:23482847; http://dx.doi. org/10.4161/onci.22789
229. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, et al. Trial Watch: Oncolytic viruses for cancer therapy. OncoImmunology 2013; 2:e24612; http://dx.doi.org/10.4161/onci.24612
230. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; PMID:22754768; http://dx.doi.org/10.4161/ onci.20459
231. Vacchelli E, Galluzzi L, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2012; 1:179-88; PMID:22720239; http://dx.doi.org/10.4161/onci.1.2.19026
232. Vacchelli E, Senovilla L, Eggermont A, Fridman WH, Galon J, Zitvogel L, et al. Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology 2013; 2:e23510; PMID:23687621; http://dx.doi.org/10.4161/onci.23510
233. Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautes-Fridman C, Galon J, et al. Trial Watch: Anticancer radioimmunotherapy. OncoImmunology 2013; 2: e25595; http://dx.doi.org/10.4161/onci.24238.
234. Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, Sato Y, et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor a2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy 2012; 14:733-42; PMID:22424217
235. Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, Komiyama M, et al. a-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer 2012; 12:623; PMID:23270484; http://dx.doi.org/10.1186/1471-2407-12-623
236. Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, et al. Phase I trial of a multiepitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother 2013; 62:125-35; PMID:22847020; http://dx.doi.org/10.1007/s00262-012-1319-0
237. Fong B, Jin R, Wang X, Safaee M, Lisiero DN, Yang I, et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One 2012; 7:e32614; PMID:22485134; http:// dx.doi.org/10.1371/journal.pone.0032614
238. Zahradova L, Mollova K, Ocadlikova D, Kovarova L, Adam Z, Krejci M, et al. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results. Neoplasma 2012; 59:440-9; PMID:22489700; http://dx.doi. org/10.4149/neo_2012_057
239. Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 2013; 73:19-29; PMID:23087058; http://dx.doi. org/10.1158/0008-5472.CAN-12-1127
240. Tel J, Aarntzen EH, Baba T, Schreibelt G, Schulte BM, Benitez-Ribas D, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013; 73:1063-75; PMID:23345163; http://dx.doi.org/10.1158/0008-5472.CAN-12-2583
241. Oshita C, Takikawa M, Kume A, Miyata H, Ashizawa T, Iizuka A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012; 28:1131-8; PMID:22895835
242. Sharma A, Koldovsky U, Xu S, Mick R, Roses R, Fitzpatrick E, et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 2012; 118:4354-62; PMID:22252842; http://dx.doi.org/10.1002/ cncr.26734
243. Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa Y, Lee Y, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012; 41:1601-9; PMID:22971679
244. Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, Lin SZ, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg 2012; 77:736-44; PMID:22120301; http://dx.doi. org/10.1016/j.wneu.2011.08.020
245. Himoudi N, Wallace R, Parsley KL, Gilmour K, Barrie AU, Howe K, et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol 2012; 14:271-9; PMID:22484634; http://dx.doi.org/10.1007/s12094-012-0795-1
246. Florcken A, Kopp J, van Lessen A, Movassaghi K, Takvorian A, Johrens K, et al. Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: A clinical phase I/II study. Hum Vaccin Immunother 2013; 9:9; PMID:23570049; http:// dx.doi.org/10.4161/hv.24149
247. Kamigaki T, Kaneko T, Naitoh K, Takahara M, Kondo T, Ibe H, et al. Immunotherapy of autologous tumor lysate-loaded dendritic cell vaccines by a closed-flow electroporation system for solid tumors. Anticancer Res 2013; 33:2971-6; PMID:23780988
248. Chia WK, Wang WW, Teo M, Tai WM, Lim WT, Tan EH, et al. A phase II study evaluating the safety and efficacy of an adenovirus-?LMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann Oncol 2012; 23:997-1005; PMID:21821548; http://dx.doi. org/10.1093/annonc/mdr341
249. Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, et al. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012; 61:1033-43; PMID:22159452; http://dx.doi.org/10.1007/s00262-011-1176-2
250. Iclozan C, Antonia S, Chiappori A, Chen DT, Gabrilovich D. Therapeutic regulation of myeloidderived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer. Cancer Immunol Immunother 2013; 62:909-18; PMID:23589106; http://dx.doi.org/10.1007/ s00262-013-1396-8
251. Morse MA, Niedzwiecki D, Marshall JL, Garrett C, Chang DZ, Aklilu M, et al. A randomized Phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Ann Surg 2013; PMID:23657083; http://dx.doi.org/10.1097/ SLA.0b013e318292919e
252. Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 2012; 61:2033-44; PMID:22527250; http://dx.doi.org/10.1007/s00262-012-1261-1
253. Hunn MK, Hermans IF. Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines. Oncoimmunology 2013; 2:e23789; PMID:23734325; http://dx.doi.org/10.4161/onci.23789
254. Mattarollo SR, Smyth MJ. NKT cell adjuvants in therapeutic vaccines against hematological cancers. Oncoimmunology 2013; 2:e22615; PMID:23482240; http://dx.doi.org/10.4161/onci.22615
255. Hsu A, Ritchie DS, Neeson P. Are the immuno-stimulatory properties of Lenalidomide extinguished by coadministration of Dexamethasone?. Oncoimmunology 2012; 1:372-4; PMID:22737619; http://dx.doi. org/10.4161/onci.18963
256. Richter J, Neparidze N, Zhang L, Nair S, Monesmith T, Sundaram R, et al. Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. Blood 2013; 121:423-30; PMID:23100308; http://dx.doi. org/10.1182/blood-2012-06-435503
257. Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, et al. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res 2013; 19:3640-8; PMID:23685836; http://dx.doi.org/10.1158/1078-0432.CCR-13-0282
258. Aarntzen EH, Schreibelt G, Bol K, Lesterhuis WJ, Croockewit AJ, de Wilt JH, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012; 18:5460-70; PMID:22896657; http://dx.doi.org/10.1158/1078-0432.CCR-11-3368
259. Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res 2013; PMID:23722543; http:// dx.doi.org/10.1158/0008-5472.CAN-12-3058
260. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2013; 121:459-67; PMID:23212525; http://dx.doi.org/10.1182/blood-2012-06-435644
261. Tel J, Smits EL, Anguille S, Joshi RN, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells are equipped with antigen-presenting and tumoricidal capacities. Blood 2012; 120:3936-44; PMID:22966165; http://dx.doi.org/10.1182/blood-2012-06-435941
262. Tel J, van der Leun AM, Figdor CG, Torensma R, de Vries IJ. Harnessing human plasmacytoid dendritic cells as professional APCs. Cancer Immunol Immunother 2012; 61:1279-88; PMID:22294456; http://dx.doi.org/10.1007/s00262-012-1210-z
263. Aspord C, Leccia MT, Salameire D, Laurin D, Chaperot L, Charles J, et al. HLA-A(*)0201(+) plasmacytoid dendritic cells provide a cell-based immunotherapy for melanoma patients. J Invest Dermatol 2012; 132:2395-406; PMID:22696054; http://dx.doi. org/10.1038/jid.2012.152
264. Bell BD, Kitajima M, Larson RP, Stoklasek TA, Dang K, Sakamoto K, et al. The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. Nat Immunol 2013; 14:364-71; PMID:23435120; http://dx.doi.org/10.1038/ ni.2541
265. Segura E, Touzot M, Bohineust A, Cappuccio A, Chiocchia G, Hosmalin A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013; 38:336-48; PMID:23352235; http:// dx.doi.org/10.1016/j.immuni.2012.10.018
266. Guermonprez P, Helft J, Claser C, Deroubaix S, Karanje H, Gazumyan A, et al. Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med 2013; 19:730-8; PMID:23685841; http://dx.doi. org/10.1038/nm.3197
267. Banchereau J, Zurawski S, Thompson-Snipes L, Blanck JP, Clayton S, Munk A, et al. Immunoglobulinlike transcript receptors on human dermal CD14+ dendritic cells act as a CD8-antagonist to control cytotoxic T cell priming. Proc Natl Acad Sci U S A 2012; 109:18885-90; PMID:23112154; http://dx.doi. org/10.1073/pnas.1205785109
268. Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, et al. IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013; 38:970-83; PMID:23706669; http://dx.doi. org/10.1016/j.immuni.2013.04.011
269. Wong JL, Berk E, Edwards RP, Kalinski P. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res 2013.
270. Heesters BA, Chatterjee P, Kim YA, Gonzalez SF, Kuligowski MP, Kirchhausen T, et al. Endocytosis and recycling of immune complexes by follicular dendritic cells enhances B cell antigen binding and activation. Immunity 2013; 38:1164-75; PMID:23770227; http://dx.doi.org/10.1016/j.immuni.2013.02.023
271. Furuta K, Ishido S, Roche PA. Encounter with antigenspecific primed CD4 T cells promotes MHC class II degradation in dendritic cells. Proc Natl Acad Sci U S A 2012; 109:19380-5; PMID:23129633; http://dx.doi. org/10.1073/pnas.1213868109
272. Zhang Z, Bao M, Lu N, Weng L, Yuan B, Liu YJ. The E3 ubiquitin ligase TRIM21 negatively regulates the innate immune response to intracellular double-stranded DNA. Nat Immunol 2013; 14:172-8; PMID:23222971; http://dx.doi.org/10.1038/ni.2492
273. Lutz MB. How quantitative differences in dendritic cell maturation can direct TH1/TH2-cell polarization. Oncoimmunology 2013; 2:e22796; PMID:23525517; http://dx.doi.org/10.4161/onci.22796
274. Clausen BE, Girard-Madoux MJ. IL-10 control of dendritic cells in the skin. Oncoimmunology 2013; 2:e23186; PMID:23802070; http://dx.doi. org/10.4161/onci.23186
275. Mandaric S, Walton SM, Rülicke T, Richter K, Girard-Madoux MJ, Clausen BE, et al. IL-10 suppression of NK/DC crosstalk leads to poor priming of MCMV-specific CD4 T cells and prolonged MCMV persistence. PLoS Pathog 2012; 8:e1002846; PMID:22876184; http://dx.doi.org/10.1371/journal. ppat.1002846
276. Coquet JM, Ribot JC, Babala N, Middendorp S, van der Horst G, Xiao Y, et al. Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway. J Exp Med 2013; 210:715-28; PMID:23547099; http://dx.doi.org/10.1084/jem.20112061
277. Volpi C, Fallarino F, Pallotta MT, Bianchi R, Vacca C, Belladonna ML, et al. High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun 2013; 4:1852; PMID:23673637; http://dx.doi.org/10.1038/ncomms2874
278. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol 2012; 13:832-42; PMID:22842346; http://dx.doi. org/10.1038/ni.2376
279. Han D, Walsh MC, Cejas PJ, Dang NN, Kim YF, Kim J, et al. Dendritic cell expression of the signaling molecule TRAF6 is critical for gut microbiota-dependent immune tolerance. Immunity 2013; 38:1211-22; PMID:23791643; http://dx.doi.org/10.1016/j.immuni. 2013.05.012
280. Jellison ER, Turner MJ, Blair DA, Lingenheld EG, Zu L, Puddington L, et al. Distinct mechanisms mediate naive and memory CD8 T-cell tolerance. Proc Natl Acad Sci U S A 2012; 109:21438-43; PMID:23236165; http://dx.doi.org/10.1073/pnas.1217409110
281. Vitali C, Mingozzi F, Broggi A, Barresi S, Zolezzi F, Bayry J, et al. Migratory, and not lymphoid-resident, dendritic cells maintain peripheral self-tolerance and prevent autoimmunity via induction of iTreg cells. Blood 2012; 120:1237-45; PMID:22760781; http:// dx.doi.org/10.1182/blood-2011-09-379776
282. Claus C, Riether C, Schürch C, Matter MS, Hilmenyuk T, Ochsenbein AF. CD27 signaling increases the frequency of regulatory T cells and promotes tumor growth. Cancer Res 2012; 72:3664-76; PMID:22628427; http://dx.doi.org/10.1158/0008-5472.CAN-11-2791
283. Oh J, Wu N, Baravalle G, Cohn B, Ma J, Lo B, et al. MARCH1-mediated MHCII ubiquitination promotes dendritic cell selection of natural regulatory T cells. J Exp Med 2013; 210:1069-77; PMID:23712430; http://dx.doi.org/10.1084/jem.20122695
284. Aguilera-Montilla N, Chamorro S, Nieto C, Sánchez-Cabo F, Dopazo A, Fernández-Salguero PM, et al. Aryl hydrocarbon receptor contributes to the MEK/ ERK-dependent maintenance of the immature state of human dendritic cells. Blood 2013; 121:e108-17; PMID:23430108; http://dx.doi.org/10.1182/blood-2012-07-445106
285. Zietara N, Lyszkiewicz M, Puchalka J, Pei G, Gutierrez MG, Lienenklaus S, et al. Immunoglobulins drive terminal maturation of splenic dendritic cells. Proc Natl Acad Sci U S A 2013; 110:2282-7; PMID:23345431; http://dx.doi.org/10.1073/pnas.1210654110
286. Kim SJ, Gregersen PK, Diamond B. Regulation of dendritic cell activation by microRNA let-7c and BLIMP1. J Clin Invest 2013; 123:823-33; PMID:23298838
287. Wan CK, Oh J, Li P, West EE, Wong EA, Andraski AB, et al. The cytokines IL-21 and GM-CSF have opposing regulatory roles in the apoptosis of conventional dendritic cells. Immunity 2013; 38:514-27; PMID:23453633; http://dx.doi.org/10.1016/j.immuni. 2013.02.011
288. Gatto D, Wood K, Caminschi I, Murphy-Durland D, Schofield P, Christ D, et al. The chemotactic receptor EBI2 regulates the homeostasis, localization and immunological function of splenic dendritic cells. Nat Immunol 2013; 14:446-53; PMID:23502855; http:// dx.doi.org/10.1038/ni.2555
289. Segura E, Durand M, Amigorena S. Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med 2013; 210:1035-47; PMID:23569327; http://dx.doi.org/10.1084/ jem.20121103
290. Cohn L, Chatterjee B, Esselborn F, Smed-Sörensen A, Nakamura N, Chalouni C, et al. Antigen delivery to early endosomes eliminates the superiority of human blood BDCA3+ dendritic cells at cross presentation. J Exp Med 2013; 210:1049-63; PMID:23569326; http://dx.doi.org/10.1084/jem.20121251
291. Chatterjee B, Smed-Sörensen A, Cohn L, Chalouni C, Vandlen R, Lee BC, et al. Internalization and endosomal degradation of receptor-bound antigens regulate the efficiency of cross presentation by human dendritic cells. Blood 2012; 120:2011-20; PMID:22791285; http://dx.doi.org/10.1182/blood-2012-01-402370
292. Hoffmann E, Kotsias F, Visentin G, Bruhns P, Savina A, Amigorena S. Autonomous phagosomal degradation and antigen presentation in dendritic cells. Proc Natl Acad Sci U S A 2012; 109:14556-61; PMID:22908282; http://dx.doi.org/10.1073/pnas.1203912109
293. Li C, Buckwalter MR, Basu S, Garg M, Chang J, Srivastava PK. Dendritic cells sequester antigenic epitopes for prolonged periods in the absence of antigenencoding genetic information. Proc Natl Acad Sci U S A 2012; 109:17543-8; PMID:23045695; http:// dx.doi.org/10.1073/pnas.1205867109
294. Segura E, Amigorena S. Identification of human inflammatory dendritic cells. Oncoimmunology 2013; 2:e23851; PMID:23762786; http://dx.doi. org/10.4161/onci.23851
295. Onai N, Kurabayashi K, Hosoi-Amaike M, Toyama-Sorimachi N, Matsushima K, Inaba K, et al. A clonogenic progenitor with prominent plasmacytoid dendritic cell developmental potential. Immunity 2013; 38:943-57; PMID:23623382; http://dx.doi. org/10.1016/j.immuni.2013.04.006
296. Welner RS, Bararia D, Amabile G, Czibere A, Benoukraf T, Bach C, et al. C/EBPa is required for development of dendritic cell progenitors. Blood 2013; 121:4073-81; PMID:23547051; http://dx.doi. org/10.1182/blood-2012-10-463448
297. Naik SH, Perié L, Swart E, Gerlach C, van Rooij N, de Boer RJ, et al. Diverse and heritable lineage imprinting of early haematopoietic progenitors. Nature 2013; 496:229-32; PMID:23552896; http://dx.doi. org/10.1038/nature12013
298. Sathe P, Vremec D, Wu L, Corcoran L, Shortman K. Convergent differentiation: myeloid and lymphoid pathways to murine plasmacytoid dendritic cells. Blood 2013; 121:11-9; PMID:23053574; http://dx.doi. org/10.1182/blood-2012-02-413336
299. Beisner DR, Langerak P, Parker AE, Dahlberg C, Otero FJ, Sutton SE, et al. The intramembrane protease Sppl2a is required for B cell and DC development and survival via cleavage of the invariant chain. J Exp Med 2013; 210:23-30; PMID:23267013; http://dx.doi. org/10.1084/jem.20121072
300. Greter M, Lelios I, Pelczar P, Hoeffel G, Price J, Leboeuf M, et al. Stroma-derived interleukin-34 controls the development and maintenance of langerhans cells and the maintenance of microglia. Immunity 2012; 37:1050-60; PMID:23177320; http://dx.doi. org/10.1016/j.immuni.2012.11.001
301. Bauer T, Zagórska A, Jurkin J, Yasmin N, Köffel R, Richter S, et al. Identification of Axl as a downstream effector of TGF-β1 during Langerhans cell differentiation and epidermal homeostasis. J Exp Med 2012; 209:2033-47; PMID:23071254; http://dx.doi. org/10.1084/jem.20120493
302. Tussiwand R, Lee WL, Murphy TL, Mashayekhi M, Wumesh KC, Albring JC, et al. Compensatory dendritic cell development mediated by BATF-IRF interactions. Nature 2012; 490:502-7; PMID:22992524; http://dx.doi.org/10.1038/nature11531
303. Greter M, Helft J, Chow A, Hashimoto D, Mortha A, Agudo-Cantero J, et al. GM-CSF controls nonlymphoid tissue dendritic cell homeostasis but is dispensable for the differentiation of inflammatory dendritic cells. Immunity 2012; 36:1031-46; PMID:22749353; http://dx.doi.org/10.1016/j.immuni.2012.03.027
304. Wang Y, Szretter KJ, Vermi W, Gilfillan S, Rossini C, Cella M, et al. IL-34 is a tissue-restricted ligand of CSF1R required for the development of Langerhans cells and microglia. Nat Immunol 2012; 13:753-60; PMID:22729249; http://dx.doi.org/10.1038/ni.2360
305. Bergmann H, Yabas M, Short A, Miosge L, Barthel N, Teh CE, et al. B cell survival, surface BCR and BAFFR expression, CD74 metabolism, and CD8-dendritic cells require the intramembrane endopeptidase SPPL2A. J Exp Med 2013; 210:31-40; PMID:23267016; http:// dx.doi.org/10.1084/jem.20121076
306. Nizzoli G, Krietsch J, Weick A, Steinfelder S, Facciotti F, Gruarin P, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T cell responses. Blood 2013; PMID:23794066; http://dx.doi.org/10.1182/blood-2013-04-495424
307. Meixlsperger S, Leung CS, Rämer PC, Pack M, Vanoaica LD, Breton G, et al. CD141+ dendritic cells produce prominent amounts of IFN-a after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood 2013; 121:5034-44; PMID:23482932; http://dx.doi.org/10.1182/blood-2012-12-473413
308. Haniffa M, Shin A, Bigley V, McGovern N, Teo P, See P, et al. Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity 2012; 37:60-73; PMID:22795876; http:// dx.doi.org/10.1016/j.immuni.2012.04.012
309. Meredith MM, Liu K, Darrasse-Jeze G, Kamphorst AO, Schreiber HA, Guermonprez P, et al. Expression of the zinc finger transcription factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med 2012; 209:1153-65; PMID:22615130; http:// dx.doi.org/10.1084/jem.20112675
310. Seré K, Baek JH, Ober-Blöbaum J, Müller-Newen G, Tacke F, Yokota Y, et al. Two distinct types of Langerhans cells populate the skin during steady state and inflammation. Immunity 2012; 37:905-16; PMID:23159228; http://dx.doi.org/10.1016/j.immuni. 2012.07.019
311. Poulin LF, Reyal Y, Uronen-Hansson H, Schraml BU, Sancho D, Murphy KM, et al. DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues. Blood 2012; 119:6052-62; PMID:22442345; http://dx.doi.org/10.1182/blood-2012-01-406967
312. Roothans D, Smits E, Lion E, Tel J, Anguille S. CD56 marks human dendritic cell subsets with cytotoxic potential. Oncoimmunology 2013; 2:e23037; PMID:23524451; http://dx.doi.org/10.4161/ onci.23037
313. Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJ, Griffioen AW, et al. Functional characterization of a STAT3-dependent dendritic cellderived CD14(+) cell population arising upon IL-10-driven maturation. Oncoimmunology 2013; 2:e23837; PMID:23734330; http://dx.doi.org/10.4161/ onci.23837
314. Haniffa M, Collin M, Ginhoux F. Identification of human tissue cross-presenting dendritic cells: A new target for cancer vaccines. Oncoimmunology 2013; 2:e23140; PMID:23802067; http://dx.doi. org/10.4161/onci.23140
315. van de Laar L, van den Bosch A, Boonstra A, Binda RS, Buitenhuis M, Janssen HL, et al. PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function. Blood 2012; 120:4982-91; PMID:23091295; http://dx.doi.org/10.1182/blood-2012-02-413229
316. Weigert A, Weichand B, Sekar D, Sha W, Hahn C, Mora J, et al. HIF-1a is a negative regulator of plasmacytoid DC development in vitro and in vivo. Blood 2012; 120:3001-6; PMID:22936665; http://dx.doi. org/10.1182/blood-2012-03-417022
317. Faget J, Bendriss-Vermare N, Gobert M, Durand I, Olive D, Biota C, et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012; 72:6130-41; PMID:23026134; http://dx.doi. org/10.1158/0008-5472.CAN-12-2409
318. Conrad C, Gregorio J, Wang YH, Ito T, Meller S, Hanabuchi S, et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3(+) T-regulatory cells. Cancer Res 2012; 72:5240-9; PMID:22850422; http://dx.doi. org/10.1158/0008-5472.CAN-12-2271
319. Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, et al. Impaired IFN-a production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72:5188-97; PMID:22836755; http://dx.doi.org/10.1158/0008-5472.CAN-11-3468
320. Yu H, Huang X, Liu X, Jin H, Zhang G, Zhang Q, et al. Regulatory T cells and plasmacytoid dendritic cells contribute to the immune escape of papillary thyroid cancer coexisting with multinodular non-toxic goiter. Endocrine 2012; Forthcoming; PMID:23264145; http://dx.doi.org/10.1007/s12020-012-9853-2
321. Sawant A, Ponnazhagan S. Role of plasmacytoid dendritic cells in breast cancer bone dissemination. Oncoimmunology 2013; 2:e22983; PMID:23526329; http://dx.doi.org/10.4161/onci.22983
322. Bobr A, Igyarto BZ, Haley KM, Li MO, Flavell RA, Kaplan DH. Autocrine/paracrine TGF-β1 inhibits Langerhans cell migration. Proc Natl Acad Sci U S A 2012; 109:10492-7; PMID:22689996; http://dx.doi. org/10.1073/pnas.1119178109
323. Weber M, Hauschild R, Schwarz J, Moussion C, de Vries I, Legler DF, et al. Interstitial dendritic cell guidance by haptotactic chemokine gradients. Science 2013; 339:328-32; PMID:23329049; http://dx.doi. org/10.1126/science.1228456
324. Lamsoul I, Métais A, Gouot E, Heuzé ML, Lennon-Duménil AM, Moog-Lutz C, et al. ASB2a regulates migration of immature dendritic cells. Blood 2013; Forthcoming; PMID:23632887; http://dx.doi. org/10.1182/blood-2012-11-466649
325. Segura E, Valladeau-Guilemond J, Donnadieu MH, Sastre-Garau X, Soumelis V, Amigorena S. Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med 2012; 209:653-60; PMID:22430490; http://dx.doi. org/10.1084/jem.20111457
326. Seré K, Felker P, Hieronymus T, Zenke M. TGFβ1 microenvironment determines dendritic cell development. Oncoimmunology 2013; 2:e23083; PMID:23687620; http://dx.doi.org/10.4161/ onci.23083
327. Diana J, Simoni Y, Furio L, Beaudoin L, Agerberth B, Barrat F, et al. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat Med 2013; 19:65-73; PMID:23242473; http://dx.doi.org/10.1038/nm.3042
328. Frleta D, Ochoa CE, Kramer HB, Khan SA, Stacey AR, Borrow P, et al. HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest 2012; 122:4685-97; PMID:23160198; http:// dx.doi.org/10.1172/JCI64439
329. Prada N, Antoni G, Commo F, Rusakiewicz S, Semeraro M, Boufassa F, et al. Analysis of NKp30/ NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2013; 2:e23472; PMID:23802087; http://dx.doi. org/10.4161/onci.23472
330. Srivastava RM, Lee SC, Andrade Filho PA, Lord CA, Jie HB, Davidson HC, et al. Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients. Clin Cancer Res 2013; 19:1858-72; PMID:23444227; http://dx.doi.org/10.1158/1078-0432.CCR-12-2426
331. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013; 73:2493-504; PMID:23418322; http:// dx.doi.org/10.1158/0008-5472.CAN-12-4241
332. Munir S, Andersen GH, Met O, Donia M, Frøsig TM, Larsen SK, et al. HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res 2013; 73:1764-76; PMID:23328583; http://dx.doi. org/10.1158/0008-5472.CAN-12-3507
333. Faget J, Sisirak V, Blay JY, Caux C, Bendriss-Vermare N, Ménétrier-Caux C. ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4(+) T cells by plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e23185; PMID:23802069; http://dx.doi. org/10.4161/onci.23185
334. Schreiber TH, Wolf D, Bodero M, Podack E. Tumor antigen specific iTreg accumulate in the tumor microenvironment and suppress therapeutic vaccination. Oncoimmunology 2012; 1:642-8; PMID:22934256; http://dx.doi.org/10.4161/onci.20298
335. Pinto A, Rega A, Crother TR, Sorrentino R. Plasmacytoid dendritic cells and their therapeutic activity in cancer. Oncoimmunology 2012; 1:726-34; PMID:22934264; http://dx.doi.org/10.4161/ onci.20171
336. Fonteneau JF, Guillerme JB, Tangy F, Grégoire M. Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells. Oncoimmunology 2013; 2:e24212; PMID:23762802; http://dx.doi.org/10.4161/onci.24212
337. van den Loosdrecht AA, Santegoets SJ, van Wetering S, Kaugh Singh S, Koppes M, Hall A, et al. Allogeneic dendritic cell (DC) vaccination as an "off the shelf " treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study.. J Clin Oncol 2013; abstract 3029
338. Boehrer S, Adès L, Braun T, Galluzzi L, Grosjean J, Fabre C, et al. Erlotinib exhibits antineoplastic offtarget effects in AML and MDS: a preclinical study. Blood 2008; 111:2170-80; PMID:17925489; http:// dx.doi.org/10.1182/blood-2007-07-100362
339. Yang Y, Lizée G, Hwu P. Strong emerging rationale for combining oncogene-targeted agents with immunotherapy. Oncoimmunology 2013; 2:e22730; PMID:23524978; http://dx.doi.org/10.4161/ onci.22730
340. Kantarjian H, Jabbour E, Grimley J, Kirkpatrick P. Dasatinib. Nat Rev Drug Discov 2006; 5:717-8; PMID:17001803; http://dx.doi.org/10.1038/nrd2135
341. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260-70; PMID:20525995; http://dx.doi.org/10.1056/NEJMoa1002315
342. Talpaz M, Shah NP, Kantarjian H, Donato N, Nicoll J, Paquette R, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-41; PMID:16775234; http:// dx.doi.org/10.1056/NEJMoa055229
343. Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, Iadarola MJ, et al. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 1975; 132:434-9; PMID:810520; http://dx.doi.org/10.1093/infdis/132.4.434
344. Kroemer G, Zitvogel L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012; 1:407-8; PMID:22754758; http://dx.doi.org/10.4161/ onci.20074
345. Mothersill C, Seymour CB. Radiation-induced bystander effects--implications for cancer. Nat Rev Cancer 2004; 4:158-64; PMID:14964312; http:// dx.doi.org/10.1038/nrc1277
346. Prise KM, O'Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer 2009; 9:351-60; PMID:19377507; http://dx.doi. org/10.1038/nrc2603
347. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009; 15:6267-76; PMID:19789309; http://dx.doi. org/10.1158/1078-0432.CCR-09-1254
348. Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, von Euw E, et al. Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One 2010; 5:e12711; PMID:20856802; http://dx.doi.org/10.1371/journal. pone.0012711
349. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012; 1:1223-5; PMID:23243584; http://dx.doi. org/10.4161/onci.21335
350. Madan RA, Heery CR, Gulley JL. Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity. Oncoimmunology 2012; 1:1167-8; PMID:23170267; http://dx.doi. org/10.4161/onci.20591
351. Lee SK, Surh CD. Role of interleukin-7 in bone and T-cell homeostasis. Immunol Rev 2005; 208:169-80; PMID:16313348; http://dx.doi.org/10.1111/j.0105-2896.2005.00339.x
352. Sportès C, Gress RE, Mackall CL. Perspective on potential clinical applications of recombinant human interleukin-7. Ann N Y Acad Sci 2009; 1182:28-38; PMID:20074272; http://dx.doi.org/10.1111/j.1749-6632.2009.05075.x
353. Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, et al. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate 1999; 39:291-7; PMID:10344219; http://dx.doi.org/10.1002/ (SICI)1097-0045(19990601)39:4291::AIDPROS10 3.0.CO;2-9
354. Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011; 187:6130-42; PMID:22048768; http://dx.doi.org/10.4049/jimmunol.1102209
355. Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, et al. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 2012; 32:5363-9; PMID:23225438
356. Tongu M, Harashima N, Monma H, Inao T, Yamada T, Kawauchi H, et al. Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo. Cancer Immunol Immunother 2013; 62:383-91; PMID:22926062; http://dx.doi.org/10.1007/s00262-012-1343-0
357. Holcmann M, Drobits B, Sibilia M. How imiquimod licenses plasmacytoid dendritic cells to kill tumors. Oncoimmunology 2012; 1:1661-3; PMID:23264929; http://dx.doi.org/10.4161/onci.22033
358. Hotz C, Bourquin C. Systemic cancer immunotherapy with Toll-like receptor 7 agonists: Timing is everything. Oncoimmunology 2012; 1:227-8; PMID:22720251; http://dx.doi.org/10.4161/onci.1.2.18169
359. Walter A, Schäfer M, Cecconi V, Matter C, Urosevic-Maiwald M, Belloni B, et al. Aldara activates TLR7-independent immune defence. Nat Commun 2013; 4:1560; PMID:23463003; http://dx.doi.org/10.1038/ ncomms2566
360. Richel O, de Vries HJ, van Noesel CJ, Dijkgraaf MG, Prins JM. Comparison of imiquimod, topical fluorouracil, and electrocautery for the treatment of anal intraepithelial neoplasia in HIV-positive men who have sex with men: an open-label, randomised controlled trial. Lancet Oncol 2013; 14:346-53; PMID:23499546; http://dx.doi.org/10.1016/S1470-2045(13)70067-6
361. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3:196-200; PMID:11812998; http://dx.doi.org/10.1038/ni758
362. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-94; PMID:16809734; http://dx.doi. org/10.1200/JCO.2005.04.5252
363. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670-9; PMID:19536890; http://dx.doi.org/10.1002/ cncr.24429
364. Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ 2013; Forthcoming; PMID:23811849; http://dx.doi. org/10.1038/cdd.2013.72
365. de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, Gerritsen MJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9:5091-100; PMID:14613986
366. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23:5779-87; PMID:16110035; http://dx.doi.org/10.1200/ JCO.2005.06.478
367. Paczesny S, Banchereau J, Wittkowski KM, Saracino G, Fay J, Palucka AK. Expansion of melanoma-specific cytolytic CD8+ T cell precursors in patients with metastatic melanoma vaccinated with CD34+ progenitorderived dendritic cells. J Exp Med 2004; 199:1503-11; PMID:15173207; http://dx.doi.org/10.1084/ jem.20032118
368. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Löwik MJ, Berends-van der Meer DM, Essahsah F, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci U S A 2010; 107:11895-9; PMID:20547850; http://dx.doi. org/10.1073/pnas.1006500107